Drug intelligence / Profile preview

LY3981314

Development stage: Phase 1
Lead developer: Eli Lilly
Administration: Subcutaneous

Overview

LY3981314 is an investigational drug currently being evaluated in clinical trials for its safety and metabolism in healthy participants. The drug is administered subcutaneously (under the skin) and is in early-stage clinical development, specifically phase 1. No detailed information is publicly available on its mechanism of action, therapeutic class, molecular target, or indications beyond its investigation in healthy volunteers to assess pharmacokinetics and safety[1][3][5][7].

Beyond the preview

Go deeper on LY3981314.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3981314.

Explore the full profile